Gabapentin tablets are indicated for management of postherpetic neuralgia in adults; and as an adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy.
Granules now have a total of 55 ANDA approvals from US FDA (53 final approvals and 2 tentative approvals).
The current annual U.S. market for Gabapentin tablets is approximately $145 million, according to MAT Jan 2023, IQVIA/IMS Health.
Hyderabad-based Granules India is a vertically integrated fast growing Indian pharmaceutical company. It is present in the manufacturing of entire value chain - from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs).
The company reported 23.24% jump in net profit to Rs 124.32 crore on a 15% increase in revenue from operations to Rs 1,146.12 crore in Q3 FY23 over Q3 FY22.
Shares of Granules India fell 4.61% to Rs 271 on Tuesday, 28 March 2023.
Powered by Capital Market - Live News